Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2014 Jul 17;5(16):7126–7137. doi: 10.18632/oncotarget.2227

X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis

Zipeng Cao 1,2, Xueyong Li 3, Jingxia Li 2, Wenjing Luo 1, Chuanshu Huang 2, Jingyuan Chen 1
PMCID: PMC4196189  PMID: 25216527

Abstract

The inhibitor of apoptosis protein XIAP (X-linked inhibitor of apoptosis protein) is a well-documented protein that is located in cytoplasm acting as a potent regulator of cell apoptosis. Here, we showed that expressing XIAP with RING (Really Interesting New Gene) domain deletion (XIAPΔRING) in cancer cells promoted cancer cell anchorage-independent growth and G1/S phase transition companied with increasing cyclin e transcription activity and protein expression. Further studies revealed that XIAPΔRING was mainly localized in nuclear with increased binding with E2F1, whereas XIAP with BIR (Baculoviral IAP Repeat) domains deletion (XIAPΔBIRs) was entirely presented in cytoplasma with losing its binding with E2F1, suggesting that RING domain was able to inhibit BIR domains nuclear localization, by which impaired BIRs binding with E2F1 in cellular nucleus in intact cells. These studies identified a new function of XIAP protein in cellular nucleus is to regulate E2F1 transcriptional activity by binding with E2F1 in cancer cells. Our current finding of an effect of XIAPΔRING expression on cancer cell anchorage-independent growth suggests that overexpression of this protein may contribute to genetic instability associated with cell cycle and checkpoint perturbations, in addition to its impact on cellular apoptosis.

Keywords: XIAP, RING domain, cell cycle progression, E2F1

INTRODUCTION

Disequilibration between cell proliferation and apoptosis has been identified for a momentous mechanism of tumorigenesis. The X-linked inhibitor of apoptosis protein (XIAP) is a member of a larger family of proteins called IAPs (inhibitors of apoptosis), which is defined by a common characteristic ~80 amino acid domain named Baculoviral IAP Repeat (BIR) [1-3]. The BIR domains that can vary in number from one to three in different IAPs are indispensable for their anti-apoptotic activity. The RING finger domain of XIAP possesses E3 ubiquitin ligase activity, and appears to be responsible for self-degradation of these IAPs through the proteasome, in response to certain apoptotic stimuli [4]. The RING domain may not only function as negative regulator of the IAPs, for example, the RING finger of cIAP1 mediates the ubiquitination of caspases-3 and -7 [5]. The RING finger of XIAP can also mediate an interaction with Bone Morphogenetic Protein Receptor-1A (BMPR-1A), with the BIR region subsequently recruiting TAB1 (TAK1 Binding Protein 1)/TAK1 (TGF-β-activated Kinase 1) complexes to the receptor [6]. It was reported that XIAP can activate Nuclear Factor kappa B (NF-κB) through the activation of TAK1 [7], although it is still unknown whether these activities are independent of the anti-caspase and E3 ubiquitin ligase activities of XIAP. Recently, XIAP was found to inhibit cIAP-2 auto-degradation through binding with BIR2 and BIR3 domains of c-IAP2 by RING finger to enhance IκB-α phosphorylation on serines 32 and 36[8]. In this context, it appears that XIAP functions as an adapter molecule necessary for cancer cell signaling.

Despite the overall sequence and structural similarity among the IAP family members, the subcellular distribution of IAPs seems extremely variable. For example, survivin is predominantly a nuclear protein, and its expression is cell cycle dependent, peaking at G2-M in normal cells [9]. Moreover, high levels of nuclear c-IAP1 are predictive of poor overall survival and local recurrence-free survival in cervical squamous cell carcinomas, and are shown to be independent of prognostic factors by multivariate analysis [10]. Although XIAP is expressed mostly in the cytoplasm, and less extent in nuclear in normal cells [11], its higher nuclear expression is correlated with lower survival rate in breast carcinoma patients [12]. In addition, the biological function and mechanisms of nuclear XIAP is not explored yet.

In mammalian cells, the E2F family is composed by eight members and the diversity found in this family reflects distinct roles in the transcriptional regulation and cell function [13]. E2F1-3, forming heterodimers with DP proteins, functions primarily as transcriptional activators; in contrast, E2F4-8 acts mainly as transcriptional repressors. The transcription factor E2F family members have been well known for their ability to regulate cell cycle progression by coordinating a large group of genes involved in regulation of G1 to S phase transition [13]. G1 phase progression in mammalian cells is mediated by the activities of Cyclin D1-CDK4 (or CDK6) and Cyclin E-CDK2. At the molecular level, during G1/S, the Cyclin E–CDK2 complex hyperphosphorylates retinoblastoma protein (RB), and leads to the dissociation of E2F1 from RB and in turn initiates E2F-dependent transcriptional activity. It is therefore thought to be critical for normal cells to tightly regulate cyclin E activity; indeed, alteration of the E2F/Cyclin E axis is well-known to be involved in the cancer development in various types of tumor [13, 14].

In current study, we examined the effect of intracellular distribution of XIAP, the contribution of the BIR and RING domains to XIAP intracellular localization, and explored biological function of altering XIAP localization. Our findings indicate that XIAP is predominantly a cytoplasmic protein, and its nuclear localization is regulated by RING domain. We also found that overexpression of XIAP with the deletion of RING domain mainly localizes in nuclear and promotes aberrant cell division and anchorage-independent growth by binding with E2F1 in nuclear, in turn leading to E2F1 transactivation and Cyclin E induction.

RESULTS

The differential role of XIAP RING domain and its E3 ligase in promotion of cancer cell anchorage-independent growth and cell cycle G1/S phase transition

In our previous study, we reported that XIAP RING domain and its E3 ligase activity are required for XIAP's upregulation of cyclin d1 transcription and cancer cell growth [15], whereas XIAP RING domain and not its E3 ligase plays an important role in XIAP binding with RhoGDIα and inhibits RhoGDIα SUMOylation [16, 17]. To determinate whether there was a differential role of RING domain and its E3 ligase in regulation of cancer growth, we compared the capabilities of anchorage-independent growth of XIAP−/−(vector), XIAP−/−(HA-XIAP), XIAP−/−(HA-XIAPΔRING), and XIAP−/−(XIAPH467A) in 0.33% soft agar. The results unexpectedly showed that transfection of XIAPΔRING resulted in significant increase in colony formation, while those transfected with XIAPH467A showed an inhibition on colony formation as we reported before [15] (Figs. 1A & 1B). This result suggests that XIAP RING domain has an essential function in regulating cancer cell growth independent of its E3 ligase activity.

Figure 1. Promotion of cancer cell anchorage-independent growth and G1/S phase cell cycle transition by ectopic expression of XIAPΔRING.

Figure 1

Open in a new tab

(A & B) anchorage-independent cell growth of various HCT116 cell stable transfectants was evaluated in soft agar assay. The colony formation was observed and the photograph images were taken under an inverted microscope (A) and numbers of colonies were scored, and presented as colonies per 1×104 seeded cells (B). The symbol (*) indicates a significant increase of colony formation in XIAP−/−(HA-XIAP) cells in comparison to that in XIAP−/−(vector) transfectant (p<0.05); symbol of “#” indicates a significant increase of colony formation in XIAP−/−(HA-XIAPΔRING) as compared with that of XIAP−/−(HA-XIAP) transfectant; symbol of “#” shows a significant decrease of colony formation in XIAP−/−(HA-XIAPH467A) cells as compared with XIAP−/−(HA-XIAPΔRING) transfectant. Each bar indicates the mean and standard derivation of three independent experiments. (C & D) cell cycle profile was determined by PI staining with FACS analysis in the transfectants as indicated. Representative histograms of cell cycle profiles were presented (C) and percentage of cells in the G0/G1, S, and G2/M phases were presented from three independent experiments (D).

To determine the potential association of anchorage-independent growth with cell cycle alterations, we assessed the cell cycle status of the transfectants by DNA content analysis using flow cytometry. The results indicated ectopic expression of XIAPΔRING, XIAP−/−(HA-XIAPΔRING) exhibited accelerated progression in the G1/S phase of the cell cycle, resulting in decreased G0/G1 proportion (54.93% vs 82.69%) as compared to XIAP−/−(vector) cells, whereas the cell cycle profile of XIAPH467A transfectant did not show this promotion in G1/S phase transition (G0/G1 proportion: 77.10% vs 82.69%) (Figs. 1C & 1D). Taken together, these data suggest that accelerated growth of XIAPΔRING expressing cells might be associated with promotion of G1/S phase cell cycle transition.

Ectopic expression of XIAPΔRING upregulated Cyclin E expression, which was essential for XIAPΔRING-mediated abnormal cancer cell growth

It is known that Cyclins and CDK inhibitors are responsible for regulation of G1 to S transition [18]. To explore the molecular mechanisms underlying XIAP RING domain in triggering cell cycle alterations, Western blot analysis was used to identify expressions of HA-XIAP, HA-XIAPΔRING, HA-XIAPΔBIRs and HA-XIAPH467A in the various stable transfectants as indicated in Fig. 2A. The protein expression levels of Cyclins as well as p27 were further evaluated and compared in the transfectants. As shown in Figs. 2B and 2C, the markedly increased Cyclin E expression was only observed in XIAP−/−(HA-XIAPΔRING) cells and not in any other transfectants. Consistent with our previous report [15], XIAP−/−(vector) and XIAP−/−(HA-XIAPH467A) cells showed a remarkable reduction of Cyclin D1 protein expression in comparison to that in XIAP−/−(HA-XIAP) cells, and p27 expression was not markedly affected. Therefore, our results demonstrated that XIAP RING domain was crucial for XIAP regulation of Cyclin E protein expression that is independent of its E3 ligase activity.

Figure 2. Ectopic expression of XIAPΔRING in XIAP−/− cells resulted in upregulation of Cyclin E protein expression.

Figure 2

Open in a new tab

(A) stable HCT116 XIAP−/− cell transfectants used in our study were identified by Western blot. (B & C) the cells were synchronized by incubation of cells with 0.1% FBS medium for 24h. The cells were then cultured in 2% FBS medium for 24 h and cell extracts were subjected to Western blot for determination of protein expression as indicated (B), and quantified (C).

To investigate the potential contribution of the increased Cyclin E expression to the XIAPΔRING-mediated abnormal cancer cell growth, two independent short hairpin RNAs (shRNA) were employed to knockdown Cyclin E expression in XIAP−/−(HA-XIAPΔRING) cells[19]. As shown in Fig. 3A, transfection of shCyclin E-80 dramatically reduced Cyclin E protein expression in XIAP−/−(HA-XIAPΔRING) cells, whereas shCyclin E-81 was not able to show observable reduction of Cyclin E protein expression. Knockdown of Cyclin E expression by shRNA recapitulated the cell cycle transition phenotype of XIAP−/−(HA-XIAPΔRING) cells (S, 24.67% vs 9.85% and G0/G1 proportion: 56.65% vs 76.11%, Figure 3B). Accordingly, the cancer cell anchorage-independent growth phenotype was also blocked by knockdown of Cyclin E expression (Fig. 3C & 3D). These results demonstrated that maintaining increased Cyclin E expression was crucial for the increased cancer cell anchorage-independent growth property of XIAPΔRING domain in XIAP−/−cells.

Figure 3. Cyclin E induction was essential for XIAPΔRING promotion of cancer cell anchorage-independent growth and G1/S phase cell cycle transition.

Figure 3

Open in a new tab

(A) immunoblot analysis of Cyclin E protein levels in XIAP−/−(HA-XIAPΔRING) cells transfected with Cyclin E shRNA. (B) after synchronization of cells with 0.1% FBS medium, cells were cultured in 2% FBS medium for 24 h, and cells were then subjected to flow cytometry analysis. (C & D) stable transfectants as indicated were subjected to anchorage-independent growth assay in soft agar. The symbol (*) indicates a significant inhibition of colony formation by knockdown of Cyclin E expression (p<0.05). The colonies were expressed as mean±S.D.

XIAPΔRING regulated cyclin e transcription through E2F-dependent transcriptional activity

To elucidate the molecular mechanisms underlying the regulation of Cyclin E expression by XIAP RING domain, we transfected cyclin e promoter-driven luciferase reporter into different XIAP transfectant cells and the cyclin e promoter transcriptional activity was evaluated. The results showed that cyclin e transcription activity was upregulated in XIAPΔRING expression cells, but not XIAPH467A cells (Fig. 3A). It has been known that there are six E2F binding sites in the human cyclin e promoter and that the 3 upstream E2F binding sites are important for the upregulation of cyclin e gene transcription [20]. Thus, we examined whether XIAPΔRING enhanced E2F-dependent transcriptional activation. We transfected E2F-dependent luciferase reporter, which is driven by six tandem E2F binding sites, into XIAP−/−(HA-XIAPΔRING) cells [21]. As shown in Fig. 4B, E2F-dependent transcriptional activation was significantly upregulated in XIAP−/−(HA-XIAPΔRING) cells in compared with XIAP−/−(vector) cells (Fig. 3B). The increased cyclin e promoter transcriptional activity in XIAP−/−(HA- XIAPRING) cells was abolished by mutation of E2F binding site in cyclin e promoter-driven luciferase reporter (Fig. 3C), suggesting that the increased cyclin e promoter transcriptional activity XIAPΔRING domain was E2F-dependent [21]. Taken together, ectopic expression of XIAPΔRING could strongly activate E2F-dependent transcriptional activity, which conceivably underlies its ability to upregulation of Cyclin E expression, thereby contributing to acceleration of cancer cell anchorage-independent growth.

Figure 4. XIAPΔRING regulated cyclin e transcription via induction of E2F1 transactivation.

Figure 4

Open in a new tab

(A) the cells (1×104) stably transfected with cyclin e promoter-driven luciferase reporter were seeded into each well of a 96-well plate. After synchronization, the cells were extracted for determination of the luciferase activity, as described in our previous studies[53]. (B) the indicated transfectants that were stably transfected with (E2F)6 luciferase reporter (1×104) were seeded into each well of a 96-well plate and subjected to luciferase activity assay. (C) cells (1×104) stably transfected with cyclin e promoter reporter or cyclin e promoter reporter with E2F binding sites mutation were seeded into each well of a 96-well plate and subjected to luciferase activity assay. (D) Western blot was performed to determine the E2F1 and E2F1 target proteins expression in the indicated transfectants.

In addition to the luciferase reporter of E2F activity we also examined the steady-state expression levels of cell cycle checkpoint Cyclin A and cell apoptosis related p53, which are known to contain an E2F response element and are transcriptionally regulated by E2F1 [22, 23]. The different expression of E2F1, Cyclin A or p53 was not observed among various transfectants (Fig. 3D). These results implied that expression of XIAPΔRING accelerated anchorage-independent growth by specific upregulation of E2F- dependent Cyclin E, rather than other E2F1-targeted cell cycle and apoptosis related proteins.

XIAPΔRING localized into nuclei in cancer cells and interacted with E2F1 through BIR domain

Given the increased E2F-dependent transcriptional activity of E2F1 in XIAP−/−(HA-XIAPΔRING) cells as demonstrated above and the interaction of E2F1 and cIAP1 through BIR domain as reported in previous studies [24], we anticipated that XIAP RING domain might be able to interact with E2F1 in the intact cells. To test this notion, we carried out a co-immunoprecipitation assay as shown in Fig. 5A. Total cellular proteins from transfectants of XIAP−/−(vector), XIAP−/−(HA-XIAP), XIAP−/−(HA-XIAPΔRING), XIAP−/−(HA-XIAPH467A) and XIAP−/−(HA-XIAPΔBIRs) cells were immunoprecipitated by using anti-HA antibody-conjuncted beads. The results obtained from Western blot analysis revealed that E2F1 protein was presented in co-precipitated protein complex in XIAP−/−(HA-XIAPΔRING), but not detectable in XIAP−/−(HA-XIAPΔBIRs) cells (Fig. 5A), indicating that XIAP does interact with E2F1 through BIR domain in the cells. Since E2F1 acted as transcriptional factor in nucleus, we tested whether XIAPΔRING could translocate into nucleus. To establish the sub-cellular distribution of XIAPΔRING, we isolated cytoplasma and nuclear fractionations in various transfectants as indicated in Fig. 5B. Examination of the fractions for XIAPΔRING sub-cellular distributions showed that XIAPΔRING mainly presented in the nuclear fraction, whereas XIAPΔBIRs and XIAPH467A mainly showed in cytosolic fraction (Fig. 5B). Taken consideration of alteration of the RB-E2F axis plays an important role in cancer development in various types of tumors demonstrated in previous studies [13] and our above findings that significant increased Cyclin E protein expression, cell cycle transition promotion and anchorage-independent growth of cancer cells, we anticipated that XIAPΔRING nuclear location plays a role in the regulation of E2F transcriptional activity by its interaction with nuclear E2F1, which in turn increased E2F1-mediated transcription of its targeted gene Cyclin E.

Figure 5. Determination of XIAPΔRING protein interaction with E2F1 protein and the distribution of XIAP protein and its various deletions between cytoplasm and nuclei.

Figure 5

Open in a new tab

(A) the cell extracts from various XIAP−/− transfectants as indicated were used for immunoprecipitation with anti-HA antibodies and pull-down protein complexes were subjected to Western blot analysis. (B) cytosolic and nuclear lysates prepared from indicated cells were analyzed by Western blot as indicated.

DISCUSSION

XIAP is an important multifunctional protein with activities and purposes reaching far beyond the mere inhibition and control of cell apoptosis [15, 17, 25]. The aim of this study was to delineate possible differences in the anchorage-independent growth regulating behavior of XIAP protein lacking of BIRs or RING domain in order to more clearly explain their contribution to the synergistic or antagonistic effects on regulating cancer cell growth. Our results revealed here that exogenous XIAPΔRING could increase anchorage-independent cancer cell growth and promotion of G1/S phase transition. The further study demonstrated that XIAPΔRING translocated into nuclear and this nuclear translocation was associated with the promotion of G1/S phase transition of cancer cell cycle by binding with E2F1 protein and subsequently resulted in E2F1 transactivation and induction of transcription of cyclin e in cancer cells. Our finding of the effect of XIAPΔRING on cancer cell growth and cytokinesis suggests that nuclear XIAP might contribute to genetic instability associated with cell cycle and checkpoint perturbation. Taken together with poor clinical outcome of the cancer patients with high expression of XIAP in nuclear[12], our novel findings of XIAPΔRING in nuclear location and upregulation of E2F1/Cyclin E axis provide us significant insight into understanding of nuclear XIAP in cancer patients.

XIAPΔRING expression and its translocation into nucleus resulted in its binding and interaction with E2F1 protein, by which induced in E2F transactivation and subsequently led to an E2F-dependent cyclin E induction. Cyclin E induction elicits various effects upon cell proliferation, differentiation, and survival in a manner that is highly dependent on tissue type and cell lineage[26]. The E2F-mediated Cyclin E induction could trigger a G1/S transition and promote an anchorage-independent growth in cancer cells. Our finding of an E2F-mediated increase of Cyclin E expression upon ectopic XIAPΔRING expression implicated XIAP as a cell cycle regulator in cancer cells. Since the cyclin E gene represents one of E2F's transcriptional targets, Cyclin E and cyclin E-CDK2 kinase activity is essential for assembly of DNA prereplication complexes and for firing of DNA replication origins[27]. These functions of cyclin E are essential when nondividing cells exit the quiescent state and resume cell proliferation but may be redundant with the activities of other cell cycle regulators in continuously proliferating cells [28]. It was reported that overexpression of cyclin E2, a subtype of E-cyclins, also induced genomic instability by a typical mechanism[29]. XIAPΔRING expression and its translocation into nucleus resulted in its binding and interaction with E2F1 protein, by which induced in E2F transactivation and subsequently led to an E2F-dependent cyclin E overexpression. A cyclin E transgene that overexpresses cyclin E induces breast carcinomas in mice, and ectopic cyclin E overexpression both induces genetic instability in cultured cells and transforms rodent fibroblasts in combination with other oncogenes [30-32]. It is therefore thought that increased cyclin E activity is a hallmark of cancer cells[14]. Many studies have shown that high cyclin E protein expression in human cancers is associated with increased tumor aggressiveness and poor patient outcome[14, 33, 34]. Our results provide significant information for understanding the increased nuclear XIAP expression in cancer cells.

In addition to tumorigenesis, dysregulated cyclin E activity also causes cell lineage-specific abnormalities, such as impaired maturation due to increased cell senescence[35]. Cell senescence is a signal transduction program leading to irreversible cell cycle arrest and is also a process that limits lifespan and the proliferation of normal cells, accompanied by a distinct set of change in the cellular phenotype [36, 37]. Cellular senescence irreversibly arrests cell growth and is a major barrier that cells must overcome in order to progress to full-blown malignancy[36]. It was demonstrated that cellular senescence is associated with hyper-mitogenic drive and failure to undergo mitosis, and cyclin E was induced in senescent cells [38]. The function of cyclin E in cell senescence was discovered by two separate groups that cyclin E-CDK2 can phosphorylate c-Myc, directing a transcriptional program that opposes oncogene-induced senescence [39, 40]. Implicit to these results is the prediction that cyclin E could mediate evasion of oncogene-induced senescence for continued growth. In the scenario of cellular senescence, enforced arrest of the cell cycle in G0 (e.g., caused by an increase in p21/p27) is key to senescence [36, 37]. In our experiments, ectopic expression of XIAPΔRING exhibited accelerated progression in the G1/S phase of the cell cycle, resulting in decreased G0/G1 proportion as compared to XIAP−/−(vector) cells. This result suggested that overexpressed Cyclin E in XIAP−/−(HA-XIAPΔRING) plays a role in cell cycle regulation without cell senescence under our in vitro experimental condition. We realized that cell type and growth conditions play a critical role in determining phenotypes associated with high cyclin E expression[41] and the in vivo effect of ectopic expression of XIAPΔRING and cell senescence is under investigation in our laboratory.

Our results prompt several questions that we are investigating in ongoing work. For one, the observed translocation of XIAPΔRING into the nucleus can be brought into the account in relation to its interaction with XAF1, a cellular inhibitory factor that binds and negatively regulates the caspase-mediated XIAP cleavage [11]. XAF1 directly interacts with XIAP and antagonizes its inhibitory function on caspase activity. The nuclear localization of XIAP-XAF1 resulted in the dominance of the proapoptotic caspases as evident by the presence of decreased levels of caspases 3 and 9 in the XIAP immunoprecipitates, increased caspase 3 activity and cleaved caspase 3[11]. Taking this consideration, we hypothesize that XAF1 may be involved in regulation of XIAPΔRING translocation from cytoplasma into nuclei. The clarification of XAF1 in XIAPΔRING translocation is currently undergoing in our laboratory.

Avoidance of apoptosis is critical in the development and progression of cancer [42]. XIAP possesses three BIR domains and a carboxy-terminal RING domain. It is known that XIAP prevents caspases 9 and 3 activation through its BIR3 and the BIR2 domain, respectively, and Smac/DIABLO relieves this caspase inhibitory activity of XIAP by binding to the BIR3 domain [43, 44]. XIAP cleavage is one of the main mechanisms by which cell death programs overcome the antiapoptotic barrier posed by XIAP [45, 46], and one mechanism is a caspase-dependent cleavage of XIAP [45]. It has been reported that calpain induces a cleavage of XIAP into various fragments, by which inactivates XIAP inhibition of caspases [46]. The results from current studies demonstrated that XIAPΔRING was mainly located in the nucleus, rather than cytoplasm. We found that ectopic expression of XIAPΔRING in nuclear led to promotion of G1/S cell cycle transition and anchorage-independent growth. This raised the possibility that XIAP could positively impact cancer cell growth. XIAP protein was originally identified as modulators of caspase function to prevent apoptosis, and it is now clear that multi-faceted XIAP protein performed a much more diverse range of functions than first predicted.

The protein subcellular location has been reported to regulation of cellular biological function in many previous studies [47, 48]. For example, nuclear localization and export of cIAP1 are particularly interesting because cIAP1 has thus far been described to function in regulating the cytosolic activities of caspases and Smac [49]. Nowak D et al. demonstrated for the first time that XIAP translocation from the cytosolic compartment into the nucleus is observed upon treatment of cells with cytotoxic drugs [50]. This result implies a new unknown function of XIAP in nucleus in the context of drug-induced apoptosis. It has also been reported that XIAP nuclear labeling was a sign of unfavorable prognosis in breast invasive ductal carcinoma [12]. Our results demonstrated here that XIAPΔRING expressing cells exhibited a significant acceleration of G1/S phase transition and cancer cell anchorage-independent growth. Therefore, the presented study predominately focused on the potential regulatory role of XIAP RING domain. Since antisense oligonucleotides directed against XIAP are currently being evaluated in clinical trials and RING domain also is potent target of these agents [51], the results obtained from the current studies lead us to take a special consideration whether these drugs are able to target XIAP that is located in nucleus of cancer cells.

In summary, we demonstrated here that cancer cells transfected XIAP deletion of RING domain led to cyclin e transcription and protein expression via binding with and modulation of the E2F1 transactivation. We also showed that XIAPΔRING could translocate to the nuclear and the nuclear localization of XIAP is dependent on the BIR domains, whereas RING domain provides an inhibitory effect on XIAP translocation. More importantly, we identified that nuclear-translocated XIAPΔRING significantly promotes G1/S phase transition and anchorage-independent growth of cancer cells. Our results provide a significant insight into understanding of biological significance of the increased nuclear XIAP expression in cancer cells and poor prognosis of clinical patients with nuclear XIAP overexpression. In addition, the current studies also provide very useful information for new drug design, which can target nuclear XIAP in cancer cells. Determining the significance of our findings to mammary tumor biology is another focus of our ongoing studies.

MATERIALS AND METHODS

Cell culture and reagents

Human colon cancer cell lines HCT116 wild-type (WT) and HCT116 XIAP−/− cells, as well as their transfectants, including HCT116 WT(vector), XIAP−/−(vector), XIAP−/−(HA-XIAP), XIAP−/−(HA-XIAPΔBIRs) and XIAP−/−(HA-XIAPΔRING), were established in our previously published studies [15-17, 52]. The HCT116 cells and transfectants were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS and penicillin/streptomycin. All cells were maintained in a humidified incubator at 37°C, with a 5% CO2 humidified atmosphere. Antibodies for immunoblotting were obtained from the following sources: XIAP polyclonal antibody (BD PharMingen, San Diego, CA); XIAP monoclonal antibody, E2F1, CDK2 and GAPDH (Cell Signaling Technology Inc., Beverly, MA); Cyclin D1, Cyclin E and CDK4 (Santa Cruz Biotechnology, Santa Cruz, CA); p27 (Abcam, Cambridge, MA); HA (Covance Inc., Princeton, NJ).

Plasmids and cell transfection

The constructs of cyclin e promoter, E2F mutant cyclin e promoter and 6×E2F luciferase reporters were gifts from Dr. Daniel S. Peeper, the Netheorlands Cancer Institute [21]. Human Cyclin E specific shRNA constructs were gifts from Dr. Hanfei Ding, Georgia Health Sciences University[19]. Transfections were done using PolyJetTM DNA In Vitro Transfection Reagent (SignaGen Laboratories, Gaithersburg, MD) and Opti-MEM® reduced serum medium (Invitrogen, Carlsbad, CA). For stable transfection, cultures were subjected to blasticidin selection. These stable transfectants were cultured in the selected antibiotic-free medium for at least two passages before utilization for experiments.

Anchorage-independent growth assay

Anchorage-independent growth ability was determined in soft agar, as described in our previous studies [53]. Briefly, 3 ml of 0.5% agar in basal modified Eagle's medium supplemented with 10% FBS was layered onto each well of 6-well tissue culture plates. Cells (1×104 cells) suspended in 1 ml normal medium were mixed with 2 ml of 0.5% agar-basal modified Eagle's medium supplemented with 10% FBS, and 1 ml of mixture was added into each well over top of the 0.5% agar layer. Plates were incubated at 37°C in 5% CO2 for 2 to 3 weeks, and the colonies with more than 32 cells of each were scored and presented as colonies/104 cells.

Flow Cytometry Assay

Cell cycle analysis was performed as described previously [15]. Cells were harvested by trypsinization and washed once with PBS. The cells were then resuspended in 0.3 ml PBS (pH 7.4), and fixed by addition of ice-cold 80% ethanol. Fixation proceeded for at least overnight at -20°C. Fixed cells were centrifuged, resuspended in propidium iodide solution (50 mg/ml propidium iodide, 10 mg/ml RNase A and 0.1% Triton X-100 in PBS) (Sigma Chemical, St.Louis, MO) for at least 1 h at 4°C. The DNA content was determined by Flow Cytometry using the Epics XL FACS (Beckman Coulter, Miami, FL) and EXPO 32 software [54].

Western Blot

Cells were harvested and washed with PBS. Cell pellets were resuspended and incubated with lysis buffer (10 mM Tris-HCl, pH 7.4, 1% SDS, and 1 mM Na3VO4). Equal amounts of protein lysate were subjected to sodium dodecylsulphate polyacrylamide gel electrophoresis and electrophoretically transferred to PVDF membranes. Primary antibody and secondary alkaline phosphatase-conjugated antibody incubations were performed in 5% non-fat milk and 5% BSA solution in PBS-T (PBS with 0.1% Tween 20). Blots were detected by the enhanced chemifluorescence Western blot system (Model Storm 860, Molecular Dynamics) as described in our previous publications [55, 56]. Quantitation was analyzed densitometrically using AtlasImage software (version 2.01, Clontech Laboratories, Sunnyvale, CA).

Luciferase Reporter Assay

HCT116 cells were transfected with cyclin e promoter-luciferase, E2F mutant cyclin e promoter-luciferase and 6×E2F luciferase reporters in combination with the pRL-TK vector (Promega, Madison, WI). The transfectants were seeded into 96-well plates. After the cell density reached 70-80%, cells were treated as indicated in the figure legends, and were then extracted with luciferase assay lysis buffer (Promega, Madison, WI). The luciferase activity was determined with the Dual-Luciferase Reporter Assay System according to the manufacturer's instructions as described [57, 58].

Subcellular Fractionation

Preparation of subcellular fractions was performed as previously described [53]. The subcellular fractions were extracted according to the protocol of the Nuclear/Cytosol Fractionation Kit (BioVision Technologies, Mountain View, CA). Equal amount of protein in each sample was determined using a protein quantification assay kit (Bio-Rad, Richmond, CA). Nuclear extracts were stored at -80°C until they were used.

Immunoprecipitation

For immunoprecipitational experiments, cells transfected with the indicated plasmids were lysed in cell lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM Na3VO4, 0.5% Nonidet P-40, and complete protein mixture inhibitors from Roche Applied Science) on ice. Any insoluble material was removed by centrifugation at 16,000×g for 20 minutes at 4°C. Immunoprecipitation was carried out by incubation of cell lyses with anti-HA antibody-conjugated agarose beads. After an overnight incubation, beads were washed three times with immunoprecipitation lysis buffer, and bound proteins were subjected to Western blot assay [17].

Statistical analysis

Student's t test was utilized to determine the significance of differences between different groups. The differences were considered to be significant at P<0.05.

Acknowledgments

We thank Dr. Daniel S. Peeper from the Netherlands Cancer Institute for generous gifts of cyclin e promoter, E2F mutant cyclin e promoter and 6×E2F luciferase reporters, and Dr. Hanfei Ding from Georgia Health Sciences University for generous gifts of Cyclin E specific shRNA constructs. This work was supported in partially by grants from NIH/NCI CA165980, CA112557, CA177665, and NIH/NIEHS ES000260, NBRPC 2012CB525002, 2012CB525004 and NSFC 81230063 as well as the Program for Innovative Research Team in University (PCSIRT), Ministry of Education, China.

Abbreviations used in this paper

BIR

The Baculovirus IAP repeat

BMPR-1A

Bone Morphogenetic Protein Receptor-1A

CDK

Cyclin-dependent kinase

IAP

inhibitors of apoptosis protein

NF-κB

Nuclear factor Factor kappa B

RB

retinoblastoma protein

RING

really interesting new gene

TAB1

TAK1 Binding Protein 1

TAK1

TGF-β-activated Kinase 1

XIAP

X-linked inhibitor of apoptosis protein.

Footnotes

Author contribution

Zipeng Cao, acquisition of data and drafting of the manuscript; Xueyong Li and Jingxia Li, acquisition of data; Wenjing Luo, critical discussion and revision of the manuscript; Chuanshu Huang and Jingyuan Chen, critical revision of the manuscript and important intellectual content and study supervision.

REFERENCES

  • 1.Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. Journal of virology. 1993;67(4):2168–2174. doi: 10.1128/jvi.67.4.2168-2174.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. Journal of virology. 1994;68(4):2521–2528. doi: 10.1128/jvi.68.4.2521-2528.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Holcik M, Korneluk RG. XIAP, the guardian angel. Nature reviews Molecular cell biology. 2001;2(7):550–556. doi: 10.1038/35080103. [DOI] [PubMed] [Google Scholar]
  • 4.Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000;288(5467):874–877. doi: 10.1126/science.288.5467.874. [DOI] [PubMed] [Google Scholar]
  • 5.Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. The Journal of biological chemistry. 2000;275(35):26661–26664. doi: 10.1074/jbc.C000199200. [DOI] [PubMed] [Google Scholar]
  • 6.Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell cycle. 2008;7(8):1036–1046. doi: 10.4161/cc.7.8.5783. [DOI] [PubMed] [Google Scholar]
  • 7.Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. The Journal of biological chemistry. 2000;275(29):22064–22068. doi: 10.1074/jbc.M910346199. [DOI] [PubMed] [Google Scholar]
  • 8.Yang W, Cooke M, Duckett CS, Yang X, Dorsey JF. Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells. Cell cycle. 2014;13(6):992–1005. doi: 10.4161/cc.27880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–8589. doi: 10.1038/sj.onc.1207113. [DOI] [PubMed] [Google Scholar]
  • 10.Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer research. 2002;62(17):4860–4866. [PubMed] [Google Scholar]
  • 11.Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nature cell biology. 2001;3(2):128–133. doi: 10.1038/35055027. [DOI] [PubMed] [Google Scholar]
  • 12.Zhang Y, Zhu J, Tang Y, Li F, Zhou H, Peng B, Zhou C, Fu R. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagnostic pathology. 2011;6:49. doi: 10.1186/1746-1596-6-49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nature reviews Molecular cell biology. 2002;3(1):11–20. doi: 10.1038/nrm714. [DOI] [PubMed] [Google Scholar]
  • 14.Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. The New England journal of medicine. 2002;347(20):1566–1575. doi: 10.1056/NEJMoa021153. [DOI] [PubMed] [Google Scholar]
  • 15.Cao Z, Zhang R, Li J, Huang H, Zhang D, Zhang J, Gao J, Chen J, Huang C. X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. The Journal of biological chemistry. 2013;288(28):20238–20247. doi: 10.1074/jbc.M112.448365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu J, Zhang D, Luo W, Yu Y, Yu J, Li J, Zhang X, Zhang B, Chen J, Wu XR, Rosas-Acosta G, Huang C. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. The Journal of biological chemistry. 2011;286(18):15630–15640. doi: 10.1074/jbc.M110.176982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Liu J, Zhang D, Luo W, Yu J, Li J, Yu Y, Zhang X, Chen J, Wu XR, Huang C. E3 ligase activity of XIAP RING domain is required for XIAP-mediated cancer cell migration, but not for its RhoGDI binding activity. PloS one. 2012;7(4):e35682. doi: 10.1371/journal.pone.0035682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  • 19.Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, Huang S, Cui H, Ding HF. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene. 2012;31(33):3785–3795. doi: 10.1038/onc.2011.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(26):12146–12150. doi: 10.1073/pnas.92.26.12146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Vredeveld LC, Rowland BD, Douma S, Bernards R, Peeper DS. Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis. 2010;31(2):201–207. doi: 10.1093/carcin/bgp296. [DOI] [PubMed] [Google Scholar]
  • 22.Qin XQ, Livingston DM, Kaelin WG., Jr and Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(23):10918–10922. doi: 10.1073/pnas.91.23.10918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(14):7245–7250. doi: 10.1073/pnas.94.14.7245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, Plenchette S, Lagrange B, Hammann A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. The Journal of biological chemistry. 2011;286(30):26406–26417. doi: 10.1074/jbc.M110.191239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kenneth NS, Duckett CS. IAP proteins: regulators of cell migration and development. Current opinion in cell biology. 2012;24(6):871–875. doi: 10.1016/j.ceb.2012.11.004. [DOI] [PubMed] [Google Scholar]
  • 26.Minella AC, Loeb KR, Knecht A, Welcker M, Varnum-Finney BJ, Bernstein ID, Roberts JM, Clurman BE. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes & development. 2008;22(12):1677–1689. doi: 10.1101/gad.1650208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Geng Y, Sicinski P. Differences in regulation and function of E-cyclins in human cancer cells. Cell cycle. 2013;12(8):1165. doi: 10.4161/cc.24487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P. Cyclin E ablation in the mouse. Cell. 2003;114(4):431–443. doi: 10.1016/s0092-8674(03)00645-7. [DOI] [PubMed] [Google Scholar]
  • 29.Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell cycle. 2013;12(4):606–617. doi: 10.4161/cc.23512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Molecular and cellular biology. 1997;17(1):453–459. doi: 10.1128/mcb.17.1.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Current biology : CB. 2002;12(21):1817–1827. doi: 10.1016/s0960-9822(02)01225-3. [DOI] [PubMed] [Google Scholar]
  • 32.Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(10):4089–4094. doi: 10.1073/pnas.0606537104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer research. 2000;60(2):242–244. [PubMed] [Google Scholar]
  • 34.Dong Y, Sui L, Tai Y, Sugimoto K, Hirao T, Tokuda M. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6(11):4253–4258. [PubMed] [Google Scholar]
  • 35.Siu KT, Rosner MR, Minella AC. An integrated view of cyclin E function and regulation. Cell cycle. 2012;11(1):57–64. doi: 10.4161/cc.11.1.18775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Berman AE, Leontieva OV, Natarajan V, McCubrey JA, Demidenko ZN, Nikiforov MA. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget. 2012;3(12):1522–1532. doi: 10.18632/oncotarget.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703–716. doi: 10.1016/s0092-8674(03)00401-x. [DOI] [PubMed] [Google Scholar]
  • 38.Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell cycle. 2012;11(24):4642–4649. doi: 10.4161/cc.22937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjo S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG, Amati B. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nature cell biology. 2010;12(1):54–59. doi: 10.1038/ncb2004. sup pp 51-14. [DOI] [PubMed] [Google Scholar]
  • 40.Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, Sharifi HR, Lilischkis R, Hein N, Wu S, Vervoorts J, Henriksson M, Grandien A, Luscher B, Larsson LG. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(1):58–63. doi: 10.1073/pnas.0900121106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Sengupta T, Abraham G, Xu Y, Clurman BE, Minella AC. Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis. Molecular and cellular biology. 2011;31(18):3885–3895. doi: 10.1128/MCB.05089-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
  • 43.Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388(6639):300–304. doi: 10.1038/40901. [DOI] [PubMed] [Google Scholar]
  • 44.Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO journal. 1998;17(8):2215–2223. doi: 10.1093/emboj/17.8.2215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. The EMBO journal. 1999;18(19):5242–5251. doi: 10.1093/emboj/18.19.5242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kobayashi S, Yamashita K, Takeoka T, Ohtsuki T, Suzuki Y, Takahashi R, Yamamoto K, Kaufmann SH, Uchiyama T, Sasada M, Takahashi A. Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. The Journal of biological chemistry. 2002;277(37):33968–33977. doi: 10.1074/jbc.M203350200. [DOI] [PubMed] [Google Scholar]
  • 47.Gulshan K, Thommandru B, Moye-Rowley WS. Proteolytic degradation of the Yap1 transcription factor is regulated by subcellular localization and the E3 ubiquitin ligase Not4. The Journal of biological chemistry. 2012;287(32):26796–26805. doi: 10.1074/jbc.M112.384719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Adjobo-Hermans MJ, Crosby KC, Putyrski M, Bhageloe A, van Weeren L, Schultz C, Goedhart J, Gadella TW., Jr PLCbeta isoforms differ in their subcellular location and their CT-domain dependent interaction with Galphaq. Cellular signalling. 2013;25(1):255–263. doi: 10.1016/j.cellsig.2012.09.022. [DOI] [PubMed] [Google Scholar]
  • 49.Samuel T, Okada K, Hyer M, Welsh K, Zapata JM, Reed JC. cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. Cancer research. 2005;65(1):210–218. [PubMed] [Google Scholar]
  • 50.Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leukemia & lymphoma. 2004;45(7):1429–1436. doi: 10.1080/1042819042000198858. [DOI] [PubMed] [Google Scholar]
  • 51.Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell death and differentiation. 2006;13(2):179–188. doi: 10.1038/sj.cdd.4401826. [DOI] [PubMed] [Google Scholar]
  • 52.Yu J, Zhang D, Liu J, Li J, Yu Y, Wu XR, Huang C. RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. The Journal of biological chemistry. 2012;287(17):13752–13760. doi: 10.1074/jbc.M111.337469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Fang Y, Yu Y, Hou Q, Zheng X, Zhang M, Zhang D, Li J, Wu XR, Huang C. The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP. The Journal of biological chemistry. 2012;287(42):35234–35243. doi: 10.1074/jbc.M112.389494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer research. 2005;65(20):9287–9293. doi: 10.1158/0008-5472.CAN-05-0469. [DOI] [PubMed] [Google Scholar]
  • 55.Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, Shen HM, Whiteman M, Huang C. IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol. 2006;175(4):607–617. doi: 10.1083/jcb.200602149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Song L, Li J, Ye J, Yu G, Ding J, Zhang D, Ouyang W, Dong Z, Kim SO, Huang C. p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Molecular and cellular biology. 2007;27(7):2713–2731. doi: 10.1128/MCB.00657-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Li J, Chen H, Tang MS, Shi X, Amin S, Desai D, Costa M, Huang C. PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells. J Cell Biol. 2004;165(1):77–86. doi: 10.1083/jcb.200401004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(11):5826–5830. doi: 10.1073/pnas.94.11.5826. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES